Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1011/1012/1010 Flu Vaccine Study
NCT05827068Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mRNA-1011.1, mRNA-1011.2 and mRNA-1012.1 in seasonal influenza (7 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants With Solicited Local and Systemic Adverse Reactions, Number of Participants With Unsolicited AEs and 1 more. Started Mar 2023; status: completed.
02
Drugs
mRNA-1011.1mRNA-1011.2mRNA-1012.1
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT05827068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827068.